助力中国基因和细胞治疗“弯道超车”，让“天价药”走进寻常百姓家！邦耀生物荣获“2024上海市科技进步一等奖”

Core Viewpoint - The article highlights the significant achievements of Shanghai Bangyao Biotechnology Co., Ltd. in the field of gene editing and cell therapy, particularly their recognition through the Shanghai Science and Technology Progress Award for their innovative projects in these areas [2][5]. Group 1: Award Recognition - The project "Development and Translational Application of Key Technologies in Gene Editing and Cell Therapy" won the first prize at the Shanghai Science and Technology Progress Award, marking a significant milestone for Bangyao Biotechnology [2][5]. - The award signifies the project's achievement at an internationally advanced or domestically leading level, emphasizing its substantial social and economic benefits [5][6]. Group 2: Technological Innovations - Bangyao Biotechnology is recognized as one of the earliest teams in China to apply CRISPR-Cas9 gene editing technology, having published the first successful application in mammals in 2013 [8]. - The company has developed a gene therapy for β-thalassemia, achieving a "one-time treatment, lifelong cure" for 15 patients, which has been acknowledged as a benchmark in the international field of thalassemia treatment [10]. - The non-viral PD1-CAR-T technology, developed by the team, has shown a 100% objective response rate and an 85.7% complete response rate in clinical studies, significantly improving safety and cost-effectiveness compared to traditional CAR-T therapies [12][15]. - The allogeneic universal CAR-T cell therapy, targeting CD19, has been developed to address the challenges of personalized treatment cycles and costs, allowing for immediate use and significantly reducing production costs [16][17]. Group 3: Clinical Research and Future Directions - Bangyao Biotechnology is conducting two registration clinical studies focusing on relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma, aiming to expand the application of their therapies to solid tumors and autoimmune diseases [22]. - The company has established a robust innovation platform with over 100 patents and multiple projects in clinical trials, demonstrating its commitment to advancing gene and cell therapy [25].